AlphaQuest LLC Has $97,000 Stake in ZimVie Inc. $ZIMV

AlphaQuest LLC increased its position in shares of ZimVie Inc. (NASDAQ:ZIMV) by 2,695.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,947 shares of the company’s stock after buying an additional 8,627 shares during the period. AlphaQuest LLC’s holdings in ZimVie were worth $97,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in shares of ZimVie in the first quarter valued at $98,000. Hsbc Holdings PLC acquired a new position in shares of ZimVie in the first quarter valued at $144,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of ZimVie by 5.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,127 shares of the company’s stock valued at $211,000 after purchasing an additional 836 shares during the last quarter. Wealthquest Corp acquired a new position in shares of ZimVie in the first quarter valued at $182,000. Finally, Wells Fargo & Company MN increased its holdings in shares of ZimVie by 17.8% in the fourth quarter. Wells Fargo & Company MN now owns 17,037 shares of the company’s stock valued at $238,000 after purchasing an additional 2,569 shares during the last quarter. 95.63% of the stock is currently owned by institutional investors and hedge funds.

ZimVie Trading Up 0.3%

ZIMV stock opened at $18.94 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.60 and a current ratio of 2.37. The company’s 50-day simple moving average is $15.42 and its 200 day simple moving average is $12.02. ZimVie Inc. has a 52 week low of $8.15 and a 52 week high of $19.01. The company has a market capitalization of $534.11 million, a PE ratio of -27.06 and a beta of 2.19.

ZimVie (NASDAQ:ZIMV) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.21 by $0.05. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. The business had revenue of $116.66 million for the quarter, compared to the consensus estimate of $112.60 million. As a group, sell-side analysts anticipate that ZimVie Inc. will post 0.6 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of ZimVie from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. Barclays upgraded shares of ZimVie from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $9.00 to $19.00 in a report on Tuesday, July 22nd. UBS Group decreased their price objective on shares of ZimVie from $16.00 to $10.00 and set a “neutral” rating on the stock in a report on Thursday, May 15th. Finally, B. Riley downgraded shares of ZimVie from a “buy” rating to a “neutral” rating and set a $19.00 price objective on the stock. in a report on Thursday, July 31st. Four research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.75.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.